David Detoro

This development is not surprising based on our interactions with leaders from Mirum Pharmaceuticals, Inc. at industry conferences and meetings. Mirum consistently demonstrates a clear commitment to its patient communities and to building sustainable solutions in rare disease. Their continued focus on thoughtful portfolio expansion—while maintaining depth in therapeutic expertise—reflects strong leadership and a long-term view of value creation in areas of high unmet need. It’s encouraging to see companies in the sector pairing strategic discipline with genuine patient focus. 👍 #RareDisease #BiopharmaLeadership #PharmaStrategy #Mirum #IndustryPerspective

1

Friday was a great day at #M365Philly hosted at the Microsoft office in Malvern. As always, the hardest part was choosing between overlapping sessions - there was no shortage of relevant, practical, high‑value content. A few highlights from sessions I attended: Building Real World Agents Using Copilot Studio (Jared Matfess) - grounding the agent hype in real business value and practical use cases. From Copilot to Co‑Worker (Jeff Gellman) - how Agent Mode is shifting Copilot from reactive assistant to proactive collaborator. SharePoint at 25: Lessons from the Scars (Diego Domingos da Silva) - an honest, battle‑tested view of what really works (and breaks) at scale. When One Agent Isn’t Enough (JP Pérez) - orchestration patterns and agents that check their own work. Planning Sensitivity Labels for Copilot Readiness (Karen D.) - getting information protection right before rolling out AI. Stop Searching, Start Knowing (Nishanth Shreepad) - unlocking real value with the SharePoint Knowledge Agent. Huge thanks to Jason Rivera, Thomas Daly, and Manpreet Singh for the monumental organizing effort, along with all the speaker, sponsors, and volunteers who made the event possible. The “Best Community in Tech” continues to impress, even locally. If you’re not attending these live, enriching, Microsoft community experiences, you’re missing out! Soak up the knowledge, then be sure to share with peers. Are you sponge worthy (had to)?!?!

24

1 Comment

When French pharmaceutical giant Sanofi decided to place its new U.S. headquarters in a $130 million redevelopment project in Morristown, N.J., the company cited access to a highly skilled workforce and proximity to sustainable transportation options as critical #siteselection factors. Kelly Barraza of Site Selection Magazine chronicles this major site location project that is resulting in a 375,000SF HQ with 2,000 workers. And that is just the beginning of what's happening in the Garden State. New Jersey Economic Development Authority (NJEDA) Conway Data, Inc. Industrial Asset Management Council (IAMC) Paul Hudson Ellavoz Impact Capital #economicdevelopment #workforce #jobs https://lnkd.in/d-Htcik5

5

ASCO in each year is a pivotal moment for oncology, this year is expected to be no different: 🔹 Precision medicine is moving earlier and getting more complex 🔹 Immunotherapy is evolving into smarter, biomarker-driven combinations 🔹 New targets new modalities (CAR-T, ADCs, bispecifics) are redefining treatment paradigms 🔹 Late-breaking Phase 3 data will likely and hopefully challenge current standards of care The common denominator? ➡️ More innovation… and more complexity in clinical development. At Parexel, we’re working with sponsors to translate these advances into well-designed, efficient, and truly patient-centric trials, from first-in-human to global registrational studies. If you’re attending ASCO, we’d welcome the opportunity to connect and exchange perspectives on how to navigate this rapidly evolving landscape. 📍 Let’s meet in Chicago! Elizabeth Charlotte Moser MD PhD MBA, Jim Anthony, Mike D'Ambrosio, Aaron Sosa Mejia, Tinuade Lufadeju, MA, Bernardo Haddock Lobo Goulart, Stacy Hurt 🌻and many others will be there. #ASCO26 #Oncology #ClinicalDevelopment #PrecisionMedicine #ImmunoOncology #ADCs #Radiopharmaceuticals #Parexel

32

2 Comments

In solid tumor trials, you need an imaging partner who’s immersed in the scientific advances & regulatory changes that may impact your development program. Learn how the therapeutic, modality, and regulatory expertise of your medical imaging provider can make or break your anti-tumor trial. Read the paper and learn more at #ASCO25. https://lnkd.in/eqfTDjr2

1

Cyclopharm secures 11-site agreement with University of Pennsylvania Health System, establishing immediate installations at two flagship locations with contracted rollout across nine additional sites in Pennsylvania and New Jersey. The deal positions the company within a top 20 US hospital system and creates regional density across the mid-Atlantic corridor through a single enterprise contract. 📋 Agreement Highlights: 🔹 Three-year initial term covering 11 clinical locations across the UPHS network 🔹 Immediate installations at Hospital of the University of Pennsylvania and Perelman Center for Advanced Medicine 🔹 Nine additional contracted sites for staged rollout creating installation pipeline 🔹 Potential expansion beyond 11 locations at additional UPHS-affiliated sites 🔹 Academic health system partnership providing national clinical and research influence The agreement establishes a recurring revenue model across three streams: installation fees, annual service contracts, and per-patient consumables revenue that scales with clinical utilisation. James McBrayer, Managing Director and CEO, explained: "Multi-site agreements of this nature are central to driving scalable, recurring revenue growth and improving operating leverage as utilisation increases. Establishing Technegas across multiple UPHS locations provides immediate scale and positions us for deeper institutional penetration over time." Beyond traditional pulmonary embolism diagnosis, increased clinical utilisation is expected to accelerate adoption across COPD, asthma, interstitial lung disease, and oncology-related pulmonary assessment. 📅 Upcoming Catalysts: 🔸 Installation completion at two flagship UPHS locations - Q2 2026 🔸 Staged rollout commencement across nine contracted sites - H2 2026 Found this insightful? Hit 'like' and follow for updates on Cyclopharm's multi-site UPHS rollout and broader US integrated delivery network expansion. 🔗 Read the full commercial analysis and revenue model breakdown: https://lnkd.in/gYWHf7dM

7

The complexity of drug development continues to grow—and success today depends on more than just scientific innovation.   I found this recent article from Jennifer Cannon, President, Commercial Operations, Pharma Services Group, to be a great perspective on how execution across CMC, manufacturing, and supply is becoming just as critical to keeping programs on track.   It’s a timely reminder of how important alignment, scalability, and flexibility are—especially during key transitions like tech transfer and global expansion.   Take a look: https://lnkd.in/e9EiZjcC   #DrugDevelopment #Biopharma #CMC #Manufacturing  Jennifer Cannon  

20

1 Comment

Improving clinical trials: Veristat’s first female CEO plans to double revenue, workforce Read the full article: https://lnkd.in/gvFfugjj What changes do you see shaping the future of clinical development over the next five years? We’d love to hear your perspective in the comments. #Biotech #ClinicalDevelopment #BiotechInnovation

13

ALX Oncology Holdings Inc. has announced the appointment of Jeff Knight, M.P.H., as their new Chief Development and Operating Officer. 🎉 With over 30 years of experience in clinical development, regulatory affairs, and operational execution, Jeff brings an impressive track record, notably advancing oncology programmes from early development to commercialisation. Prior to this, he held significant roles at Crinetics Pharmaceuticals, Poseida Therapeutics, and Amgen. #Biotechnology #Oncology

6

We were pleased to present the ORCA-OL exit interview data today at #SRNT2026 in Baltimore. The analysis summarizes experiences among participants receiving Achieve Life Sciences investigational treatment, cytisinicline, adding to the understanding of longer-term use in adults who smoke and are striving to quit nicotine.

117

1 Comment

Maryland Rosenfeld Franklin, VP and enterprise head of cell and gene therapy at Labcorp, will be speaking at this year’s Cell and Gene Therapy Summit in Orlando, FL. In her keynote session, “Strategies to Advance CAR T-Cell Therapy Development,” she will share how biomarkers and utilization of a novel cell production technology in the preclinical setting can provide solutions to some of the key challenges limiting advancement of adoptive cell therapies. Download our white paper to learn more from Maryland and other cell and gene therapy specialists at Labcorp. https://lnkd.in/egZ824jY

76

3 Comments

What a way to celebrate my 2-week anniversary with PhaseWell Research! 🚀 The energy here is unmatched. It’s one thing to hear about a company’s mission, but seeing the team in action—especially with the exciting news of our acquisition of Chase Medical Research, LLC—has been a major highlight. Seeing firsthand how the team is working to connect more communities to life-changing medical research has been inspiring. This expansion into Connecticut with new sites in Waterbury and Hamden is a testament to that goal. I’m proud to be part of a company that is truly shaping the future of medicine. Check out the official announcement here: PhaseWell Research Acquires Chase Medical Research #PhaseWellResearch #ClinicalTrials #MedicalInnovation #TeamWork #Growth

24

Harmony is a standout example of a Philly-area biotech that skillfully balances strong commercial success with pipeline growth. It serves as a powerful reminder of the exciting opportunities and inevitable challenges that come with scaling a biotech company. https://lnkd.in/eS4Q3HuG #ThisIsIH

3

"California-based nonprofit Prime Healthcare Foundation has acquired regional provider Central Maine Healthcare, expanding its presence on the East Coast." "As part of the deal, Prime Foundation will assume full ownership of three hospitals, two senior care facilities, a medical college, a cancer care center and over 40 physician practices in central, western, and mid-coast Maine." "Prime Foundation ... has agreed to invest $150 million over the next five years into the system’s facilities, services and infrastructure, according to a Monday announcement." "Central Maine had posted at least two years of operating losses, including an approximately $30 million loss in fiscal year 2024 and a $19 million loss in 2025. Additionally, Central Maine said the healthcare needs of its population would continue to increase as its community ages... Without the acquisition and investment, Central Maine —which serves about 400,000 patients and employs over 600 clinicians in the state — told regulators its financial position would “continue to deteriorate.” "Prime Foundation is an affiliate of for-profit hospital operator Prime Healthcare. Prime, which operates over 50 hospitals across the country, bills itself as a hospital turnaround firm." "Prime Foundation now owns hospitals in Maine, Texas, Ohio, California, Rhode Island, Pennsylvania, Illinois and Georgia. It has over $2 billion in assets, including funds donated from affiliate Prime Healthcare’s founder and CEO, Dr. Prem Reddy, and his family. Prime Foundation is led by Prime Healthcare’s chief medical officer of strategy, Dr. Kavitha Bhatia." https://lnkd.in/gWnh2cZ8

4

Maryland Rosenfeld Franklin, VP and enterprise head of cell and gene therapy at Labcorp, will be speaking at this year’s Cell and Gene Therapy Summit in Orlando, FL. In her keynote session, “Strategies to Advance CAR T-Cell Therapy Development,” she will share how biomarkers and utilization of a novel cell production technology in the preclinical setting can provide solutions to some of the key challenges limiting advancement of adoptive cell therapies. Download our white paper to learn more from Maryland and other cell and gene therapy specialists at Labcorp. https://lnkd.in/g_FnKJ-Q

4

Off the back of the surplus of interest in the 1st LEAN Cell & Gene Meeting in Boston, we’re excited to announce the launch of the 2nd LEAN Cell & Gene Meeting 📣 📅 November 6, 2025 | National Harbor, MD Full agenda here: https://ter.li/c7czb0 With investment at historic lows and manufacturing inefficiencies limiting patient access, the need for LEAN principles in CGT has never been greater. This one-day event will bring together leading voices across development, manufacturing, and quality to share practical strategies for cutting waste, stabilizing operations, and scaling advanced therapies. Conveniently scheduled the day before #SITC 2025, this meeting is the next step in building a more accessible, industrialized future for cell and gene therapy. #CellTherapy #GeneTherapy #LEANManufacturing #Biotech #CGT

25

1 Comment

Are you heading to #DCAT in #NYC ? #CDMOworld's and Pharmaceutical Leader Emma Trivella will be there interviewing leaders and heads of CDMO's. Follow CDMO World to learn the very latest insights from top CDMO's. #cdmo #pharmaceuticals #drugdevelopment #dcatweek #dcat2026 Ray Sison Kevin Bittorf

4

We are thrilled to see NewYorkBIO launch Empire Advantage, a powerful resource for our life sciences community. This rebranded member savings program offers targeted, industry-specific discounts on essential business and lab services, helping startups and growing companies stay focused on innovation while reducing operational costs. No fee to participate for NewYorkBIO members, just impactful support for advancing science. Learn more: https://lnkd.in/euBuW9ka #EmpireAdvantage #NewYorkBIO #LifeSciences #BiotechInnovation #StartupSupport #NYEcosystem

15

New Jersey just took an important step to protect patients from higher out-of-pocket costs. With Governor Murphy’s signature on the Ensuring Fairness in Cost-Sharing Amounts Act, third-party discounts and payments must now count toward patients’ copays, coinsurance, deductibles, and other out-of-pocket costs.    This reform has been years in the making and helps ensure patients get the full benefit of assistance intended to make care more affordable. Another strong example of states leading on health care policy.   #HealthPolicy #PatientAccess #HealthCareAffordability

37